They know to kind of think about it and manage it pretty well. We adjust some of our cost structure is also as a result of that. So I think the team has got a good formula here how to manage it. And we’ll just have to see how this kind of plays out.
Vijay Kumar: That’s helpful, Robert. And my second one, I know you touched upon PFA. I think Abbott’s launching their own PFA at some point in fiscal 2025, 2026. How should we think in the interim, right? I think your peer had some pretty robust assumptions for what percentage of procedures would be PFA. Is Abbott concerned about share loss when you think about that medium-term time frame? And are there offsets to it, right? When you haven’t touched upon Lingo. I think previously you had said Lingo could be as big as Libre, where are we on the Lingo launch?
Robert Ford: Yes. So we’ll have to see how — what other companies report to go to see if we’re gaining or losing share right now. But I’d say we still have got good robust growth. I’d say as we look into 2024, I’d expect us to grow generally in line with market, which has historically been double digits. We’ve got some good innovation that’s rolling out on the RF side. And as we’ve spoken about our EP business, we talk about PFA. That’s going to be a product that’s going to be really geared towards AF ablation, you still have BT and SVT ablations, where we do have good positions over there. A good portion of our sales are also on the mapping side and the mapping and the diagnostics and those consumables. So I see those being less impacted also.
So I’d say for 2024, we’ve got a good opportunity with our AP portfolio to be growing there in line with the market. And I think to the previous question, yes, we’ve got plenty of different shots on goal here to be able to deliver our high single-digit growth rates. And we’ve got a very rich portfolio, and we’re in exciting markets. Yes, Lingo, we didn’t touch on it because it wasn’t asked, but now that you have asked, yes, it is a great growth opportunity for us. We’re launching it in the U.K., I’d say, I’d call it more of a controlled launch, Vijay, to understand kind of the marketing mix, the marketing messaging, the positioning, the inner positioning with Libre and the learnings we’ve got are fantastic. And I’m excited about a full-on launch in the U.K. starting next year.
And then the opportunity to be able to bring that here to the U.S. I’ve been public about our intention to file Lingo here in the U.S. by the end of the year. And I think that’s going to provide another great opportunity for growth for us also.
Vijay Kumar: Understood. Thanks guys.
Operator: Thank you. Our next question will come from Matt Miksic from Barclays. Your line is open.
Matt Miksic: Hey. Thanks so much for taking the questions and for all the great color today. So I kind of maybe follow up on a couple of pipeline opportunities and growth drivers, one being TRILUMINATE and TriClip, sort of if you could maybe walk us through the expected pathway for commercialization in the U.S. on that front? And then back to diabetes, I know the GLP-1s dominated to the discussion there, but with Tandem rolling out integration with their pump and kind of making wider availability here of closed-loop integration in Q4. Just it would be great to hear your thoughts on what that ramp looks like, what additional support or efforts you expect will be required on your end? And just what we can expect over the next 12 months, 18 months that’s out there and available to patients. Thanks.
